Take a closer look at the latest research progress in the field of heart disease in 2016
In 2016, researchers have made tremendous progress in the field of cardiology, enabling us to better develop strategies to prevent, diagnose and treat cardiovascular diseases. So, which studies are unique this year?
Currently, cardiovascular disease (CVD) remains a major global killer, accounting for 31% of all deaths.
Because of this, heart researchers are particularly concerned with how to stop the disease, how to diagnose the disease more accurately, and how to find better treatments.
It is reported that this year's research progress in the field of heart disease includes the calculation of potential risks based on genetic markers. If emergency medical services can directly send patients to the center of percutaneous coronary intervention, ST-segment elevation myocardial infarction (STEMI) can be reduced. Mortality.
In this review, we reviewed some of the most popular and potential research advances in the field of heart disease in 2016.
(1) Progress in preventing cardiovascular disease
1) New statin guide
This is 70 years after the Framingham Risk Score was launched, and researchers continue to study the risk stratification and prevention of cardiovascular disease.
In November of this year, the US Preventive Services Task Force (USPSTF) updated the statin guidelines and presented a strong piece of evidence based on primary prevention recommendations (Level B recommendations):
1. For those 40-75 years of age who meet the following criteria, low- to moderate-intensity statins are recommended for primary prevention of cardiovascular disease: one or more cardiovascular risk factors (LDL-C > 3.4 mmol/L and / or HDL-C <1.0 mmol / L, diabetes, high blood pressure, smoking) and the risk of cardiovascular events in 10 years is 7.5-10%;
2. All adults over the age of 40, if one or more of dyslipidemia, diabetes, high blood pressure or smoking, provide a low to moderate dose of statin in patients with a cardiovascular disease risk of more than 10% for more than 10 years. Drugs;
3. There is still insufficient evidence to support the use of statins for primary prevention in people aged 76 years or older.
2) Using genetics to determine the risk of cardiovascular disease
The future of risk stratification may include genetics, which is missing from the 10-year calculation. Clinical use may be somewhat deviated, but research is based on early prediction of genomic risk scores, especially when added to traditional calculations.
Genetic factors play an important role in the development of coronary heart disease (CHD), but the clinical application of genomic risk score (GRSS) is not clear relative to clinical risk scores, such as the Framingham risk score (FRS).
A study published in the September issue of the European Heart Journal found that for people over 60 years of age: Integrating GRS with FRS or ACC/AHA13 scores can improve outcomes from 10-year risk predictions based on large numbers of single nucleotide polymorphisms The GRS improves the risk prediction of CHD and encodes a different life risk trajectory captured from traditional clinical risk scores.
Clear Medical Face Shield Splash Protection Antifog Mask
Face Shield
Luck Medical Consumables Co.,LIMITED , https://www.luckmedical.com